Institute for Cancer Research

Kjetil Taskén
Instiute head

Institute for Cancer Research has since its foundation in 1954 played a central role within the field of cancer research both in Norway and internationally. The Institute has seven research departments and more than 320 employees, master students included. About 70% of the employees and projects are externally funded. Read more

See introductory video with welcome to the ICR 

See full video covering all of ICR and its Departments 

Publication overview

Annual reports

 

Current news and events

Discovered gene patterns can predict prostate cancer treatment response

The Norwegian team. 
From left: Dr. Alfonso Urbanucci and Dr. Nikolai Engedal
The Norwegian team. From left: Dr. Alfonso Urbanucci and Dr. Nikolai Engedal

Approximately 5,000 Norwegian men are diagnosed with prostate cancer each year. Perhaps the most significant clinical challenge today is deciding which type of treatment will work best for different patient groups. In the study "Single-cell ATAC and RNA sequencing reveal pre-existing and persistent cells associated with prostate cancer relapse" led by Dr Alfonso Urbanucci from Oslo University Hospital and Professor Matti Nykter from Tampere University, and published in Nature Communications, the researchers found that specific patterns in gene expression and DNA organization can predict patient response to treatment.

Publication from The Norwegian Cancer Genomics Consortium in Genome Medicine

Anita Sveen and Bjarne Johannessen
Anita Sveen and Bjarne Johannessen

Project group leaders Anita Sveen and Bjarne Johannessen at Department of Molecular Oncology at the Institute for Cancer Research are 1st and 2nd authors of a major work presenting the ”expressed mutation dose” as a determinant of the functional consequences of mutations in colorectal cancer.

The article - entitled "The expressed mutational landscape of microsatellite stable colorectal cancers" is published in the journal Genome Medicine.

Novel gene expression-based classification of metastatic colorectal cancer published in Genome Medicine

S. Hossein Moosavi, 1st author
S. Hossein Moosavi, 1st author

The multidisciplinary team of the K.G.Jebsen Colorectal Cancer Research Centre publishes a novel gene expression-based classification of metastatic colorectal cancer.
PhD student S. Hossein Moosavi in Anita Sveen’s project group at the Dept. of Molecular Oncology at the Institute for Cancer Research is 1st author of this paper published in Genome Medicine.
This is the first large study of multi-metastatic gene expression profiling of colorectal cancer liver metastases, and the new metastasis-oriented subtyping framework showed prognostic relevance in the context of tumor heterogeneity. 

Ragnhild Lothe awarded the Excellent Researcher Award at the Oslo University Hospital

From the ceremony: Vietri, Lothe and Pihlstrøm.
From the ceremony: Vietri, Lothe and Pihlstrøm.

Three Oslo University Hospital scientists received prestigous awards for their outstanding research on August 27th. The major prize - the "Excellent Researcher Award" - went to Ragnhild A. Lothe. Lasse Pihlstrøm and Marina Vietri both received the "Early Career Award".
The prize money - 300.000 and 150.000 NOK respectively - is earmarked for research activities.

The ceremony was streamed and is available via YouTube.

Announcement from the Reseach Council of Norway:Innovation Project for the Public Sector

The Research Council of Norway is announcing up to NOK 160 million in R&D support for Innovation Projects for the Public Sector. A funding of NOK 49 million is available for innovation in and for the public sector that contributes to good solutions to specific challenges in the health and welfare services. 

Funding scale: NOK 3 000 000-7 000 000

Application deadline: 15 September 2021

Units and subpages

View all subunitsHide all subunits